WINNIPEG, MANITOBA -- (MARKET WIRE) -- September 11, 2006 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it is expanding its product pipeline to include new diagnostic research programs for pancreatic and stomach cancer.
